Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
Psoriasis: Biologic treatment and liver disease
Eva Vilarrasa, Luis Puig, Psoriasis Unit, Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, 08025 Barcelona, Spain
Author contributions: All authors contributed to this paper; Vilarrasa E designed and wrote the paper; Puig L reviewed the manuscript.
Correspondence to: Eva Vilarrasa, MD, Physician Staff, Psoriasis Unit, Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, C/ Sant Antoni Maria Claret 167, 08025 Barcelona, Spain. evilarrasa@santpau.cat
Telephone: +34-93-5537007 Fax: +34-93-5537008
Received: December 29, 2013
Revised: August 28, 2014
Accepted: September 16, 2014
Published online: November 2, 2014
Processing time: 319 Days and 7.6 Hours
Revised: August 28, 2014
Accepted: September 16, 2014
Published online: November 2, 2014
Processing time: 319 Days and 7.6 Hours
Core Tip
Core tip: We review and summarize the published data regarding the efficacy and safety of anti-tumor necrosis factor-alpha and anti-interleukin-12/23 therapies in patients with psoriasis and liver diseases, with special reference to hepatitis C, hepatitis B, non-alcoholic fatty liver disease, and fatty liver disease. Data collected and revised up to December 2013.